Result card

  • ECO2: What amounts of resources are used when delivering IGG and its comparators (resource-use measurement)?
Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment
E0002
English
Guidance Resources

What amounts of resources are used when delivering IGG and its comparators (resource-use measurement)?

Authors: Anna-Theresa Renner, Neill Booth, Esther Kraft, Ingrid Rosian-Schikuta, Matthias Schwenkglenks

Internal reviewers: Pseudo297 Pseudo297

Given the lack of available data and lack of published evidence on the efficacy and/or the effectiveness of the intervention, the researchers (and internal reviewers) of this ‘Costs and economic evaluation’ - domain agreed that it would not be prudent to undertake research into costs or undertake an economic evaluation.

Renner A et al. Result Card ECO2 In: Renner A et al. Costs and economic evaluation In: Jefferson T, Cerbo M, Vicari N [eds.]. Use of Intravenous immunoglobulins for Alzeheimer’s disease including Mild Cognitive Impairment [Core HTA], Agenas - Agenzia nazionale per i servizi sanitari regionali ; 2015. [cited 7 February 2023]. Available from: http://corehta.info/ViewCover.aspx?id=267